COMMUNIQUÉS West-GlobeNewswire
-
Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026
15/10/2026 -
Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
15/10/2026 -
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
15/10/2026 -
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
15/10/2026 -
First Tracks Biotherapeutics Announces $200 Million Private Placement
15/10/2026 -
PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
15/10/2026 -
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
15/10/2026 -
Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
15/10/2026 -
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
15/10/2026 -
Nema Health Expands Access to Specialized PTSD Treatment Through Evernorth Behavioral Health Network
15/10/2026 -
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
15/10/2026 -
Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego
15/10/2026 -
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
15/10/2026 -
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
15/10/2026 -
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15/10/2026 -
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
15/10/2026 -
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
15/10/2026 -
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
15/10/2026 -
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Pages